b'2021-22 DATA SOURCEClinical Assets K E T E DA RM 5DRUGSH A S E I I CENTRAL P NERVOUS SYSTEM4DRUGSA S E I 12DRUGS ONCOLOGYP H ONCOLOGYBY MEDICAL SPECIALTY 8DRUGS 11 OTHER DRUGS11510(k)INFECTIOUS DISEASEDEVICE APPROVALS 19DRUGSONCOLOGY 18 OTHER DRUGS13DRUGSCENTRAL NERVOUS SYSTEM 2DRUGS11DRUGS CENTRAL TOTAL DEVICES OPHTHALMOLOGY NERVOUS SYSTEM29 OTHER DRUGS 5 OTHERIDRUGS I827TOTAL E IORTHOPEDIC DEVICES PHA S41 INVESTIGATIONAL | 786 APPROVED V E R Y 45DRUGSOC ONCOLOGY321TOTALI S 24DRUGS 32DRUGSDIN VITRO DIAGNOSTICS DEVICES ONCOLOGY INFECTIOUS DISEASE207 INVESTIGATIONAL | 114 APPROVED 12DRUGS 24DRUGSINFECTIOUS DISEASE CENTRAL NERVOUS SYSTEM6DRUGS 64 OTHER DRUGS191TOTAL IMMUNOLOGYCARDIOVASCULAR DEVICES60 INVESTIGATIONAL | 131 APPROVED 16 OTHER DRUGS A LI C187TOTALC L I NSPECIALIZED SECTOR DEVICES P R E23 INVESTIGATIONAL | 164 APPROVED99TOTALGENERAL SURGERY DEVICES19 INVESTIGATIONAL | 80 APPROVED613TOTAL TOTAL DRUGSOTHER DEVICES BY PHASE156 INVESTIGATIONAL | 457 APPROVED38 BIOSCIENCECOLORADO 2022-2023 2022-2023 BIOSCIENCECOLORADO 39'